Svend Andersen - Perrigo Company President
| PRGO Stock | USD 25.75 0.02 0.08% |
President
Mr. Svend Andersen is Executive Vice President, President Consumer Healthcare International of the Company since 2017.
| Age | 62 |
| Tenure | 7 years |
| Address | The Sharp Building, Dublin, Ireland, D02 TY74 |
| Phone | 353 1 709 4000 |
| Web | https://www.perrigo.com |
Latest Insider Transactions
Andersen Prior to joining Perrigo in May 2016, Mr. Andersen served as Executive Vice President Europe for LEOPharma from December 2015 to May 2016. Prior to that, he was Regional President and Corporationrationrationrate officer at Hospira, Inc.’s Europe, Middle East and Africa business for five years, was Executive Vice President responsible for the Western European division’s pharmaceuticals, generics, OTC and hospital products businesses at Actavis from 2008 to 2015 including leading Alpharma’s EMEA businesses prior to its acquisition by Actavis, and prior to that, spent 10 years with Ferrosan specialized in OTC and consumer health products as Vice President for Global Commercial Operations.Svend Andersen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Svend Andersen against Perrigo Company stock is an integral part of due diligence when investing in Perrigo Company. Svend Andersen insider activity provides valuable insight into whether Perrigo Company is net buyers or sellers over its current business cycle. Note, Perrigo Company insiders must abide by specific rules, including filing SEC forms every time they buy or sell Perrigo Company'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Svend Andersen over three months ago Disposition of 6683 shares by Svend Andersen of Perrigo Company at 27.425 subject to Rule 16b-3 | ||
Svend Andersen over six months ago Disposition of 5468 shares by Svend Andersen of Perrigo Company subject to Rule 16b-3 |
Perrigo Company Management Efficiency
The company has return on total asset (ROA) of 0.0137 % which means that it generated a profit of $0.0137 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0316) %, meaning that it created substantial loss on money invested by shareholders. Perrigo Company's management efficiency ratios could be used to measure how well Perrigo Company manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of December 2024, Return On Tangible Assets is likely to grow to -0.0028. In addition to that, Return On Capital Employed is likely to drop to 0.02. At this time, Perrigo Company's Non Currrent Assets Other are very stable compared to the past year. As of the 22nd of December 2024, Other Assets is likely to grow to about 524.2 M, while Total Assets are likely to drop about 5.7 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| David Kinard | Elanco Animal Health | 57 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Aaron Schacht | Elanco Animal Health | 52 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| Saumen Chakraborty | Dr Reddys Laboratories | 58 | |
| Samson Li | Phibro Animal Health | 52 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Jonathan Bendheim | Phibro Animal Health | 48 | |
| Sarena Lin | Elanco Animal Health | 48 | |
| MPharm MS | Dr Reddys Laboratories | 61 | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Rob Aukerman | Phibro Animal Health | 66 | |
| James Meer | Elanco Animal Health | 54 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Shiv ONeill | Elanco Animal Health | 50 | |
| Todd Young | Elanco Animal Health | 52 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
Management Performance
| Return On Equity | -0.0316 | ||||
| Return On Asset | 0.0137 |
Perrigo Company Leadership Team
Elected by the shareholders, the Perrigo Company's board of directors comprises two types of representatives: Perrigo Company inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perrigo. The board's role is to monitor Perrigo Company's management team and ensure that shareholders' interests are well served. Perrigo Company's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perrigo Company's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Orlando Ashford, Independent Director | ||
| Svend Andersen, Executive Vice President and President - Consumer Healthcare International | ||
| Donal OConnor, Independent Director | ||
| Adriana Karaboutis, Independent Director | ||
| Shannon Hukill, Director Operations | ||
| Thomas Farrington, Executive Vice President, Chief Information Officer | ||
| Todd Kingma, Executive Vice President, General Counsel, Company Secretary | ||
| Rolf Classon, Independent Chairman of the Board | ||
| Patrick LockwoodTaylor, CEO President | ||
| Raymond Silcock, Chief Financial Officer, Executive Vice President | ||
| Robert Willis, Chief Human Resource Officer, Executive Vice President | ||
| Jeffrey Kindler, Independent Director | ||
| Grainne Quinn, Executive Vice President Chief Medical Officer | ||
| Theodore Samuels, Independent Director | ||
| Eduardo Bezerra, Executive CFO | ||
| Geoffrey Parker, Independent Director | ||
| Mary ReillyBrest, Director Development | ||
| Charles Atkinson, General VP | ||
| Murray Kessler, President, Chief Executive Officer, Director | ||
| Sharon Kochan, Executive Vice President, President - RX Pharmaceuticals | ||
| Erica Mann, Independent Director | ||
| Kyle Hanson, Special Litigation | ||
| Richard Sorota, Executive Vice President, General Manager - of Consumer Self-Care Americas | ||
| Katherine Doyle, Independent Director | ||
| Catherine Schmelter, Executive Optimization | ||
| Bradley Alford, Independent Director | ||
| Alison Ives, Executive Officer | ||
| James III, Ex Americas | ||
| Bradley Joseph, Vice Communications | ||
| James Dillard, Executive Vice President, President - Consumer Self-Care Americas | ||
| Ronald Janish, Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer |
Perrigo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perrigo Company a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0316 | ||||
| Return On Asset | 0.0137 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 6.8 B | ||||
| Shares Outstanding | 136.43 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 99.94 % | ||||
| Number Of Shares Shorted | 4.02 M | ||||
| Price To Earning | 23.57 X |
Pair Trading with Perrigo Company
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Perrigo Company position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Perrigo Company will appreciate offsetting losses from the drop in the long position's value.Moving against Perrigo Stock
| 0.77 | VIRX | Viracta Therapeutics | PairCorr |
| 0.71 | VALN | Valneva SE ADR | PairCorr |
| 0.69 | DRRX | Durect | PairCorr |
| 0.59 | ME | 23Andme Holding | PairCorr |
| 0.58 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Perrigo Company could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Perrigo Company when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Perrigo Company - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Perrigo Company PLC to buy it.
The correlation of Perrigo Company is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Perrigo Company moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Perrigo Company moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Perrigo Company can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Perrigo Company PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo Company. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo Company listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Dividend Share 1.101 | Earnings Share (1.07) | Revenue Per Share 32.088 | Quarterly Revenue Growth (0.03) |
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo Company's value that differs from its market value or its book value, called intrinsic value, which is Perrigo Company's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo Company's market value can be influenced by many factors that don't directly affect Perrigo Company's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo Company's value and its price as these two are different measures arrived at by different means. Investors typically determine if Perrigo Company is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo Company's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.